Objective To explore the effect of methylprednisolone combined with interferon in the treatment patients with relapse remitting multiple sclerosis.Methods 90 patients with relapse remitting multiple sclerosis were randomly divided into experimental group and treatment group.The experimental group during the acute stage with methylprednisolone pulse therapy,remission with interferon β (IFN-β) treatment; the control group only in the acute phase with methylprednisolone pulse therapy.Results The total effective rate of methylprednisolone pulse therapy in the acute stage was 98.9％.Experimental group during the treatment with IFN-β1α,relapse rate was 30.2％ ;patients in the control group were followed up for two years,the recurrence rate was 53.3％.Experimental group and control group was significantly different ( P ＜ 0.05 ),the experimental group was significantly lower than the control group.Conclusion For relapsing-remitting MS,using MPPT could relieve acute symptom in the acute stage,and in remission using of IFN-β1α relapse prevention was a good choice for clinicians.

The abnormal changes of tumor suppressor genes such as deletion mutant,transcription inactivation or silence on human chromosome 3p (pter) are considered as a key step which is closely related to the tumorigenesis of several kinds of cancers,especially clear cell renal cell carcinoma,one kind of renal cancer.And on this basis,it has been confirmed that the deletion and downregulation of multiple 3p genes such as VHL,RASSF1A,SEMA3B,SETD2,PBRM1,NPRL2 and so on,play a vital important role in the tumorigenesis and development of clear cell renal cell carcinoma.And they provide a further way to explain the molecular mechanism of the tumorigenesis of kidney cancer.However,when the regulatory pathway and mechanism research of some genes are known to us,the other genes,especially those newly founded,which are still not clear and need to be further investigated.

As a most common algal toxin in eutrophic freshwater body, microcystins can be produced by the bloom-forming Cyanophyta microcystis, it has become a potential hazardous substance in aquatic environments for its toxic, distribution and stability. With the increasing recognition of microcystins, China had added microcystin-LR into the related water quality standards. It is very important to detect and control the microcystins in the aquatic environment. This paper systematically introduced the current situation of researches about the determination and pollution control technique of microcystins in drinking water at home and abroad in resent years and then some issues worth of paying more attention to and doing further study in pollution control in future were presented.

Objective:To compare the effects of XELOX (oxaliplatin + capectabine) regimen and FOLFOX4 (oxaliplatin + calcium leucovorin + fluorouracil) regimen on colon cancer and their influences on serum tumor markers and cytological indexes.Methods:A total of 84 patients with colon cancer treated in Wuhu Hospital of Chinese Medicine of Anhui Province from January 2016 to January 2019 were selected, and the patients were randomly divided into the observation group (XELOX regimen, 42 cases) and the control group (FOLFOX4 regimen, 42 cases) according to the random number table. The efficacy, side effects, the changes of cytological indicators and serum tumor markers before and after chemotherapy between the two groups were compared.Results:The short-term effective rate was 76.19% (32/42) in the observation group and 61.91% (26/42) in the control group, and the difference was not statistically significant (χ 2 = 2.005, P=0.156). The incidence of side effects in the observation group was lower than that in the control group [35.71% (15/42) vs. 59.53% (25/42), χ 2 = 4.773, P = 0.029]. There was no significant difference in the levels of carbohydrate antigen 199 (CA19-9), colon cancer-specific antigen (CCSA-2) and osteopontine (OPN) between the two groups before treatment (all P > 0.05); after treatment, CA19-9, CCSA-2, OPN levels were lower than those before treatment of the two groups (all P < 0.05); after treatment, CA19-9, CCSA-2, OPN levels in the observation group were lower than those in the control group (all P < 0.05). Before treatment, there was no significant difference in the levels of neutrophils to lymphocytes ratio (NLR), platelet-lymphocytes ratio (PLR), and red cell distribution width (RDW) between the two groups (all P > 0.05); the levels of NLR, PLR and RDW after treatment in the two groups were decreased compared with those before treatment (all P < 0.05); NLR, PLR and RDW levels in the observation group after treatment were lower than those in the control group (all P < 0.05). In the observation group, the recurrence rate of 1-year, 2-year, 3-year was 4.76% (2/42), 14.26% (6/42), and 19.05% (8/42), respectively; in the control group, the recurrence rate of 1-year, 2-year, 3-year was 11.90% (5/42), 21.43% (9/42), and 26.19% (11/42), respectively; there was no statistical difference between the two groups (all P > 0.05); in the observation group, the survival rate of 1-year, 2-year, 3-year was 92.86% (39/42), 78.57% (33/42), and 71.43% (30/42), respectively; in the control group, the survival rate of 1-year, 2-year, 3-year was 85.71% (36/42), 69.05% (29/42), and 64.28% (27/42), and there was no statistically significant difference between the two groups (all P > 0.05). Conclusions:XELOX regimen and FOLFOX regimen have similar short-term and long-term effects on patients with colon cancer. They both can decrease the levels of serum tumor markers and cytological indicators of patients, and improve their prognosis, while XELOX regimen has low side effects.

Rare diseases, also known as "orphan diseases", refer to diseases with very low incidence. Countries and regions define rare diseases according to epidemiological standards, economic standards of rare drugs and disease severity. The World Health Organization (WHO) has suggested the prevalence rate of less than 6.5 to 10 per 10 000 people to define rare diseases. In May 2018, "China's First List of Rare Diseases" was released, including 121 rare diseases. Most rare diseases are hereditary diseases with early onset, severe disease, and poor prognosis. About 75% of rare genetic diseases occur in the neonatal period or childhood, which are important part of human birth defects and brings a huge burden to society and families. The effective prevention and treatment of rare diseases is one of the important goals of building a "Healthy China". With the development of molecular biology technology and the continuous research and development of advanced medical products in the field of gene therapy, the level of clinical diagnosis and treatment of rare diseases has risen to a new level, which provides a possibility for the cure of some rare diseases. In China, most rare diseases rely on imported drugs, which cost a lot and bring heavy economic burden to patients. Improving the medical insurance system for rare diseases has become a difficult point in the current medical reform. This paper mainly discusses the definition of rare diseases, the research status, efforts and future development direction of rare diseases in China, in order to deepen the understanding and response of medical workers and the whole society to rare diseases.

Drug Combinations ; Drug Design ; Drugs, Chinese Herbal ; pharmacology ; Drugs, Investigational ; Humans

Endolymphatic Hydrops ; Hearing Loss, Sudden ; Humans

Adolescent ; Child ; Dyslipidemias ; diagnosis ; therapy ; Guidelines as Topic ; Humans

OBJECTIVE: To evaluate the effectiveness and safety of bromhexine for acute bronchitis. METHODS: Cochrane Library , PubMed, Embase, ISI, CBMdisc, CNKI, VIP and WanFang database were retrieved. Systematic review, meta-analysis or randomized controlled trials (RCT) comparing bromhexine with placebo, ambroxol, tanreqing and N-acetylcysteine for acute bronchitis were included. Quality assessment and Meta-analysis were performed for RCT that met the inclusion and exclusion criteria. In addition, the conclusions of the systematic review and Meta-analysis in this aspect were referred. RESULTS: Ten RCTs met the inclusion criteria, all in Chinese. No systematic review or Meta-analysis was retrieved. Five RCTs of bromhexine versus placebo were included. There was no significant difference in clinical overall efficacy [RR=1.22, 95% CI (0.88,1.69), P=0.24]. The pulmonary rale vanishing time and cough vanishing time of bromhexine were obviously shorter than that of placebo with significant difference [MD=-2.32, 95% CI (-3.34, -1.29), P < 0.00001; MD=-2.85, 95%CI(-3.12, -2.59), P < 0.00001]. Significant difference was demonstrated in adverse reaction incidence [RR=17.00, 95% CI(1.01,286.82), P=0.05]. Three RCT of bromhexine versus ambroxol were included. Outcomes of these studies could not be combined. One RCT of bromhexine versus Tanreqing were included. Meta-analysis could not be performed. One RCT of bromhexine versus N-acetylcysteine were included. Meta-analysis could not be performed. CONCLUSION: Based on current evidence, the effectiveness of bromhexine in decurtating course of pulmonary rale and cough are superior to placebo. Clinical overall efficacy is similar between bromhexine and placebo. High risk of adverse reaction incidence still exists with bromhexine. Ambroxol, Tanreqing and N-acetylcysteine exhibit better effectiveness than bromhexine, but more studies are needed to testify the results from the small quantity of studies. Copyright 2012 by the Chinese Pharmaceutical Association.

Characters of one Candida intermedia yeast strain which isolated from nature can produce ethanol from xylose-fermenting been systemic studied. In conditions 28?C, 120 r/min, 72 h, it can produce 6.480 g/L ethanol from 7% xylose and 43.70% theoretical production of ethanol from 3% xylose. It can produce up to 21.225 g/L ethanol when incubation time prolong to 156 h from 8% xylose. It also can ferment 13% glucose produce 47.647 g/L ethanol and reach 76.90% of theoretical ethanol production, respectively. Compared to CK, ethanol productivity can be improved 9.91% when add 8% xylose in three times as 3%, 2% and 3%, respectively. Glucose can be first utilized in the mixture sugar medium. When the ratio of xylose vs. glucose is 3:1in mixture sugar, the productivity of ethanol can be improving 25%.